Our Story

ABOUT MAUNA KEA TECHNOLOGIES

Mauna Kea Technologies is a global medical device company standing at the vanguard of medical innovation with its revolutionary Cellvizio® platform, the world’s first and only in vivo cellular imaging system that has transformed the landscape of clinical diagnosis and management. Offering real-time, high-magnification visualization of cellular structures, this breakthrough technology empowers physicians to make better informed decisions across a wide range of medical specialties, from oncology to immunology.

FROM ASTROPHYSICS TO MEDICINE

As an astrophysicist working at NASA – Jet Propulsion Laboratory, our Founder, Sacha Loiseau, spent many nights observing celestial objects at the Mauna Kea Observatories in Hawaii, a premier location to study and research astronomy. Mauna Kea Technologies embodies its namesake through its technological capabilities: precise and unobstructed vision of that which is invisible to the naked eye. 

OUR VISION

At Mauna Kea Technologies, we are driven by the vision of a world where every cancer diagnosis, treatment decision, and surgical intervention is guided by real-time cellular visualization. We believe in equipping healthcare professionals with the most advanced tools to detect and treat diseases effectively, enhancing patient outcomes and advancing healthcare around the world.

OUR MISSION

Our mission is to help physicians and surgeons to diagnose and treat their patients with greater confidence, using our Cellvizio platform to address urgent medical needs with precision and care. 

In order to fulfill this mission, we aim to democratize real-time in vivo cellular imaging, making it a standard part of clinical practice. With Cellvizio’s ability to provide instant cellular insights and monitor treatment efficacy in real-time, we empower clinicians worldwide to make informed, precise, and patient-specific decisions: See Cells. Change Lives.

OUR IMPACT

With over a decade and a half of clinical validation, our technology has been the subject of 1,100+ peer-reviewed publications and is utilized in hundreds of medical institutions around the world. Our commitment to clinical excellence and innovation has led to better patient care across various specialties, including oncology, gastroenterology, pulmonology, and more. We strive to have a growing global positive contribution on human lives and healthcare systems. 

OUR AMBITION

Mauna Kea Technologies continues to blaze new trails in the medical field, advancing the future of endomicroscopy and the study of cellular dynamics in living tissue, with a commitment to elevating patient care. As pioneers in the domain, we are reshaping the approach to diagnosis and treatment, promoting early detection and the potential for personalized medicine.

OUR PARTNERSHIPS

In our collaborative efforts with industry leaders such as Johnson & Johnson, Telix Pharmaceuticals, and Tasly Pharmaceutical, we are expanding the reach of our technology. Together, we’re enhancing precision medicine, in various therapeutic areas such as gastroenterology, interventional pulmonology, neurosurgery, and uro-oncology, including groundbreaking developments in robotic surgery and AI-assisted imaging tools.

OUR VALUES

Here are some of the values we cherish the most:

Excellence – scientific and professional excellence are what we strive for on a daily basis
Passion – passion for the advancement of human healthcare is our true north
Care – we care for patients, for our collaborators around the world, for our partners and shareholders and for every human life.
Resilience – we wouldn’t be here without it and neither would any innovative medical technology. 

JOIN OUR JOURNEY

As we continue to break new ground in medical imaging, we invite you to join us on this journey. Whether you are a healthcare professional, a patient, or an investor, your engagement with Mauna Kea Technologies contributes to the shared goal of revolutionizing healthcare for better, more precise, and effective treatments.

For more information, contact us or follow our progress as we forge new paths in the advanced imaging landscape.

Professional Equity Index

The Professional Equity Index is an important measure of our progress as a company. Under French law, companies are obliged to publish their results, a score out of 100 points reflecting the equal treatment of women and men in the workplace. In 2024, Mauna Kea Technologies achieved a score of 86/100, demonstrating our commitment to equal gender representation at all levels.

We continue to celebrate and promote our associates, as well as seek ways to continue creating an environment in which employees of every race, ethnicity, and gender can thrive.

To find out more about the atmosphere at our company, read the testimonials of our employees on Linkedin with the #BehindCellvizio and #MKTteam hashtags.

News

YOU MIGHT ALSO LIKE TO READ

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Find out more by downloading the

Cellvizio Brochure